Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 27, 2015 8:13 AM ET


Company Overview of Alba Therapeutics Corporation

Company Overview

Alba Therapeutics Corporation is a clinical-stage biopharmaceutical company in Maryland. The company focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of autoimmune and inflammatory diseases. It offers a technology platform based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with applications in celiac disease, asthma/COPD, and acute lung injury. The company also focuses on providing solutions for various therapeutic areas that include immune-based disorders, as well as gastrointestinal, metabolic, pulmonary, renal, and other disease...

100 International Drive

23rd Floor

Suite 1040

Baltimore, MD 21202

United States

Founded in 2004





Key Executives for Alba Therapeutics Corporation

Chief Executive Officer, President and Chief Operating Officer
Head of Quality Control
Head of Chemistry, Manufacturing, and Controls
Compensation as of Fiscal Year 2015.

Alba Therapeutics Corporation Key Developments

Alba Therapeutics Corporation Announces Positive Results of Phase IIb Trial in Celiac Disease

Alba Therapeutics Corporation announced the positive results of their Phase IIb trial evaluating its investigational product, larazotide acetate, a tight junction regulator, intended for the treatment of patients with celiac disease (CeD). The study met its primary endpoint and, based on these results, Alba has initiated planning for Phase III clinical trials for the definitive assessment of the oral peptide's efficacy and safety. The final data will be submitted for publication in the near future. The double-blind, placebo-controlled study evaluated the efficacy and safety of larazotide acetate in the treatment of 342 patients with CeD who had persistent symptoms despite being on a gluten-free diet. This is the seventh study in a broad clinical trial program for larazotide acetate that, to date, has included 828 patients with CeD. Larazotide acetate has been granted 'Fast Track' designation from the FDA.

Similar Private Companies By Industry

Company Name Region
Unimed Pharmaceuticals, LLC United States
Vanguard Pharmaceutical Corporation United States
Canna-Pet, LLC United States
Thomas Pharmaceuticals, Ltd. United States
Lyric Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Alba Therapeutics Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at